HCWB News and Press, HCW Biologics Inc. From 01/02/23

Summary I explain why I've added Organigram to my tax loss selling basket. I also review the company's performance and risks. Finally, I recap my entire 2022 tax loss selling basket of stocks, some of which I didn't have time to write up individually. Tax Loss Selling Strategy...

MIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the l...

HCW Biologics  ( NASDAQ: HCWB ) said it received U.S. patent No. 11,518,792 on Dec. 6, which contains composition claims for a novel multi-function fusion immunotherapeutic. The company noted that the patent provides intellectual property (IP) protection to its lead drug...

Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property for HCW9218 Currently in Clinical Development for Cancer MIRAMAR, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- H...

Presentation includes data on safety and dosage escalation and immune system reaction to HCW9218 No incidence of mucosal bleeding resulting from the HCW9218 TGF-β trap HCW9218 is one of the lead product candidates of HCW Biologics Inc. MI...

HCW Biologics press release ( NASDAQ: HCWB ): Q3 GAAP EPS of -$0.14. Revenue of $1.8M. : As of September 30, 2022, the Company had cash and cash equivalents and investments of $35.9 million, consisting of $26.2 million in cash and cash equivalents and $9.7 million in l...

MIRAMAR, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting ...

HCW Biologics press release ( NASDAQ: HCWB ): Q2 GAAP EPS of -$0.66 misses by $0.53 . On June 30, 2022, the Company’s cash balance was $42.1 million, consisting of $15.4 million in cash and cash equivalents, $17.0 million in short-term investments, and $9.7 mill...

MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting ...

MIRAMAR, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grad...